US Government As Represented by the Secretary of the Army

Other

Doria R Dubois

Kenneth H Eckels

Bruce L Innis

Charles H Hoke

Joseph R Putnak

David Vaughn

Yong Cheol Shin

Hyun Su Kim

Sun Pyo Hong

J Robert Putnak

Sung Hee Lee

Soo Ok Kim

Wang Don Yoo

Wellington Sun

Niranjan Kanesa-Thasan

Sun Wellington

Niranjan Kanessa-thasan

Sang Bum Moon

Yong Ju Chung

Joseph R Puniak

Ashok K Srivastava

Niranian Kanesa-thasan

Leonard N Binn

Erik A Henchai

Kevin Cassidy

Joseph B Putnak

The present invention provides vaccine compositions of attenuated dengue virus. More specifically, the attenuated virus is produced by serial passage in PDK cells. The invention also provides methods for stimulating the immune system of an individual to induce protection against all four dengue virus serotypes by administration of attenuated dengue-1, dengue-2, dengue-3, and dengue-4 virus.

Multivalent dengue virus vaccine

The present invention provides vaccine compositions of attenuated dengue-4 virus. More specifically, the attenuated virus is produced by serial passage in PDK cells. The invention also provides methods for stimulating the immune system of an individual to induce protection against dengue-4 virus by administration of attenuated dengue-4 virus.

Attenuated dengue-4 virus vaccine

The present invention provides immunogenic compositions of attenuated dengue-1 virus. More specifically, the attenuated virus is produced by serial passage in PDK cells. The invention also provides methods for stimulating the immune system of an individual to induce protection against dengue-1 virus by administration of attenuated dengue-1 virus.

Attenuated dengue-3 virus vaccine

The present invention provides vaccine compositions of attenuated dengue-2 virus. More specifically, the attenuated virus is produced by serial passage in PDK cells. The invention also provides methods for stimulating the immune system of an individual to induce protection against dengue-2 virus by administration of attenuated dengue-2 virus.

Attenuated dengue-2 virus vaccine

An attenuated Japanese encephalitis virus adapted to Vero cell by passages on Vero cell is disclosed. A Japanese encephalitis vaccine comprising said attenuated virus is also disclosed.

Attenuated Japanese encephalitis virus adapted to Vero cell and a Japanese encephalitis vaccine

An inactivated dengue virus vaccine to immunize and protect humans against dengue fever is described. The vaccine is based on dengue viruses which have been propagated to high titers in suitable cells, purified and inactivated under conditions which destroy infectivity but preserve immunogenicity, a high level of which is demonstrated in animal models. Uses of the inactivated dengue virus for detecting antibodies to dengue and kits therefor are also described.

Method and kit for detection of dengue virus

Growing community of inventors

Wheaton, MD, United States of America

Doria R Dubois